OTSUKA-PHARMACEUTICAL
- Establishment of the new company will further support Otsuka's rapid growth in Europe which has been more than two-fold over the past 5 years.
- The European market comprises 25%* of the total global pharmaceutical market making a strong European presence in clinical drug development essential.
- Otsuka Europe Development and Commercialisation Ltd. is Otsuka's 9 th research and development institute.
Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced the formation of Otsuka Europe Development and Commercialisation Ltd. (OEDC).
Established on July 1st , 2013, OEDC is an important milestone for Otsuka's growing European pharmaceutical business and a significant long-term investment for Otsuka in Europe. OEDC will be Otsuka's European Research and Development Headquarters, working alongside Otsuka Pharmaceutical Europe Ltd (OPEL) to ensure the successful development and commercialisation of our products.
"We are delighted to establish this new company in the UK," said Dean Haubrich, President and CEO of OEDC. "We believe that Otsuka has a great deal to contribute to the health and well-being of people in Europe and we look forward to reinforcing our strong, positive presence."
OEDC and OPEL are separate entities based in the same location, just outside London. This business model allows for optimal collaboration and is a critical success factor in the evolution of our global business. Our research and development and commercial operations teams will work closely together, with aligned goals, to build one fully integrated European company which will enable us to effectively respond to the increasingly rigorous regulatory environment.
"The opening of OEDC is a very important milestone for Otsuka in Europe," said Ole Vahlgren, President and CEO of OPEL "This significant long-term investment will strengthen Otsuka Europe's continued efforts to bring Otsuka's innovative medicines to patients across Europe."
* (C)2013 IMSHealth. Calculated based on IMS World Review 2013 (Executive Summary) Reprinted with permission
|
About Otsuka Europe Development & Commercialisation Ltd. |
||
|
Company Name: |
Otsuka Europe Development and Commercialisation Ltd. | |
|
Date of Foundation: |
1st July 2013 | |
|
Capital: |
€1 million | |
|
CEO & President: |
Dean Haubrich | |
|
Head Office: |
Hunton House, Highbridge Estate, Oxford Road, Uxbridge, Middlesex, UB8 1LX, United Kingdom | |
|
Scope of Business: |
Research and Development | |
About Otsuka Pharmaceutical Co., Ltd.
Otsuka Pharmaceutical Co., Ltd. is a global healthcare company with the corporate philosophy: 'Otsuka-people creating new products for better health worldwide.' Otsuka researches, develops, manufactures and markets innovative and original products, with a focus on pharmaceutical products for the treatment of diseases and nutraceutical products for the maintenance of everyday health.
In pharmaceuticals, Otsuka is a leading firm in the challenging area of mental health and for several decades has been active in research on tuberculosis, a significant global public health issue. These commitments illustrate more powerfully than words how Otsuka is a "big venture" company at heart, applying a youthful spirit of creativity in everything it does.
Otsuka is a wholly owned subsidiary of Otsuka Holdings Co., Ltd., the holding company for the Otsuka Group. The chairman Akihiko Otsuka is the third generation of Otsuka family members to lead the business, whose origins date from 1921. The Otsuka Group has business operations in 25 countries and regions around the world, with consolidated sales of approximately USD13 billion or €10 billion for fiscal year 2012 (4/1/2012-3/31/2013). Otsuka welcomes you to visit its global website at https://www.otsuka.co.jp/en
Contact:
Otsuka media contacts
Europe:
Otsuka
Pharmaceutical Europe Ltd.
Alison Ross, +44-(0)-1895-207122,
+44-(0)-7768-337128 (m)
aross@otsuka-europe.com
or
Japan:
Otsuka
Pharmaceutical Co., Ltd.
Jeffrey Gilbert, +81-3-6361-7379,
+81-80-8728-6039 (m)
gilbert.jeffrey@otsuka.jp
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
IFF Completes Divestiture of Pharma Solutions Business Unit1.5.2025 08:00:00 CEST | Press release
IFF (NYSE: IFF) today announced that it has successfully completed the previously announced divestiture of its Pharma Solutions business unit to Roquette. “The completion of our Pharma Solutions divestiture represents a significant milestone for IFF as we delivered our targeted net debt to credit-adjusted EBITDA of below 3.0x,” said Erik Fyrwald, IFF CEO. “This is an important step as it allows us to focus on our core strategy – capitalizing on the exciting growth opportunities within our key businesses – as we maximize long-term value for our shareholders. We’d like to thank our Pharma Solutions colleagues for their unwavering commitment and their dedication to exceptional customer service. We wish them continued success as they find a new home with Roquette.” Welcome to IFF At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that
More Impact, Together: Varian and Siemens Healthineers Portfolios Highlight More Impact, Innovations and More Breakthroughs Throughout Cancer Care Journey at ESTRO 20251.5.2025 08:00:00 CEST | Press release
Varian, a Siemens Healthineers company, will showcase an integrated portfolio designed to streamline workflows, and aiming to enhance patient experience and improve patient outcomes from screening to survivorship at the 2025 European Society for Radiotherapy and Oncology (ESTRO) annual meeting, May 2-6, in Vienna, Austria. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250430039992/en/ At Varian, a Siemens Healthineers company, we envision a world without fear of cancer. For more than 75 years, Varian has developed, built, and delivered innovative technologies and solutions that help care providers around the globe treat millions of patients each year. Today, as a Siemens Healthineers company, we support every step of the cancer care journey – from screening to survivorship. From advanced imaging and radiation therapy to comprehensive software and services, to interventional radiology, we are harnessing the power of our pers
REI Super Selects SS&C For Superannuation Administration1.5.2025 05:00:00 CEST | Press release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that REI Super (“REI”), the superannuation fund for Australia’s real estate industry, has signed a long-term agreement to partner with SS&C. REI selected SS&C to serve as the fund’s administrator following a competitive tender process. SS&C Global Investor & Distribution Solutions (GIDS) will provide REI with superannuation administration services and streamlined operations support to its 24,000 members across Australia. REI will benefit from SS&C’s local administration expertise, supported by its global investment in digital service channels, automation and artificial intelligence to enhance the member experience. “As one of Australia’s longest-standing superannuation funds, our focus has always been on serving our members,” said Jarrod Coysh, CEO of REI Super. “SS&C’s extensive track record in fund administration and innovative technology make them the ideal operations partner to help us best meet our members’ needs.” “W
Svante and Mercer International Advance Carbon Capture Project at Alberta Pulp Mill1.5.2025 03:25:00 CEST | Press release
Svante Technologies Inc. (Svante), a leader in carbon capture and removal technology, today announced that its joint carbon capture and storage project with Mercer International Inc. (Mercer) has advanced to the Front-end Engineering and Design Phase 2 (FEL-2). Also known as Pre-FEED, this phase involves engineering, cost estimation, and risk analysis to evaluate the project's commercial viability. Mercer is a global producer of sustainably sourced forest products, including pulp, lumber, mass timber, biomass-based green energy, and bioextractives. The carbon capture project targets biogenic CO2 emissions from Mercer’s Peace River pulp mill, where the biomass (fibre) is sourced from sustainably managed forests. Advancing to the Pre-FEED stage will support further development of the integrated design, cost estimates, and risk assessments—key steps toward a final investment decision and potential implementation. This milestone reflects the growing momentum for carbon capture solutions wi
Andersen Global udvider sin europæiske værdiansættelseskapacitet gennem samarbejde med Value & Risk Valuation Services1.5.2025 03:03:00 CEST | Pressemeddelelse
Andersen Global fortsætter med at styrke sin værdiansættelseskapacitet gennem en samarbejdsaftale med Value & Risk Valuation Services, et fremtrædende europæisk værdiansættelsesfirma med hovedsæde i Tyskland og kontorer i Luxembourg og Østrig. Value & Risk Valuation Services blev grundlagt i 1996 og er et ledelsesejet firma, der har specialiseret sig i værdiansættelse af finansielle aktiver på tværs af forskellige aktivklasser og med varierende kompleksitet. Firmaet leverer også supplerende tjenester, herunder uafhængig prisverifikation (IPV), risikoanalyse og analyse af transaktionsomkostninger. Siden 2009 har virksomheden været ledet af Gil Bender, som er dedikeret til at levere kundecentrerede værdiansættelsesløsninger af høj kvalitet. Som en af de få europæiske udbydere, der tilbyder eksterne værdiansættelsestjenester i overensstemmelse med det europæiske direktiv om forvaltere af alternative investeringsfonde (AIFMD), opretholder Value & Risk de højeste industristandarder for over
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum